Orexigen ($OREX) says that it's enrollment of patients in a closely-watched safety study of its weight drug Contrave is happening much faster than expected. And that could trigger a quicker read-out on the data than had been initially expected. Enrollment in the study, slated to end on the 87th cardiovascular incidence, should be complete in the first quarter. And that last event could now occur in the second half of next year. Orexigen has fallen behind Arena ($ARNA), which won approval for lorcaserin. Now Vivus ($VVUS) is about to find out the fate of Qnexa. Story